drugset / Trial / NCT01485536
A Study of the HSP90 Inhibitor AUY922
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if AUY922 can help to control refractory or recurrent lymphoma. The safety of AUY922 will also be studied. AUY922 is designed to block tumor growth by blocking a protein.
Timeline
- Start
- 2012-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUY922 | Small molecule | 70 mg/m2 | Intravenous |